Answers are grounded in this paper and cite their sources.
Jin Jun Luo, William Wallace, and John W. Kusiak The FDA approved a new drug: lecanemab (or BAN2401, brand name Leqembi, Biogen and Eisai) for treating Alzheimer’s disease (AD) on January 6th, 2023, under the accelerated approval pathway.
No takes yet. Share an insight, caveat, or question.
A 2023 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: